# US 2012/0252811 A1 · Combinations of therapeutic agents for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252811 A1
- Document ID: US20120252811A1
- Status: Published application
- Kind: A1
- Application number: 13/437,458
- Filed: 2012-04-02
- Published: 2012-10-04
- Earliest claimed: 2006-04-05
- Inventors: Gregory Peter Burke; Ronald Richard Linnartz; Paul W. Manley; Richard William Versace
- Web page: https://patentgrep.com/patent/US20120252811A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a combination comprising a Bcr-Abl, c-Kit and PDGF-R tyrosine kinase inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.

## Claims

### Claim at position 1

1-35. (canceled)

### Claim 36

A combination of:
(a) a Bcr-Abl, c-Kit and PDGF-R tyrosine kinase inhibitor of formula I
wherein R1 represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, or phenyl-lower alkyl; R2 represents hydrogen, lower alkyl, optionally substituted by one or more identical or different radicals R3, cycloalkyl, benzcycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted; and R3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amino, mono- or disubstituted amino, cycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted; or wherein R1 and R2 together represent alkylene with four, five or six carbon atoms optionally mono- or disubstituted by lower alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, lower alkoxy, amino, mono- or disubstituted amino, oxo, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms; oxaalkylene with one oxygen and three or four carbon atoms; or azaalkylene with one nitrogen and three or four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy-lower alkyl, carbamoyl-lower alkyl, N-mono- or N,N-disubstituted carbamoyl-lower alkyl, cycloalkyl, lower alkoxycarbonyl, carboxy, phenyl, substituted phenyl, pyridinyl, pyrimidinyl, or pyrazinyl; R4 represents hydrogen, lower alkyl, or halogen; and a N-oxide or a pharmaceutically acceptable salt of such a compound; and
(b) one or more protein phosphatase inhibitors selected from the group consisting of a Type I protein phosphatase inhibitor (PP1 inhibitor), a Type II protein phosphatase inhibitor (PP2 inhibitor), and a protein tyrosine phosphatase (PTP) inhibitor; for simultaneous, concurrent, separate or sequential use in treating a proliferative disease.

### Claim 37

A pharmaceutical composition comprising:
(a) a Bcr-Abl, c-Kit and PDGF-R tyrosine kinase inhibitor of formula I
wherein R1 represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, or phenyl-lower alkyl; R2 represents hydrogen, lower alkyl, optionally substituted by one or more identical or different radicals R3, cycloalkyl, benzcycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted; and R3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amino, mono- or disubstituted amino, cycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted; or wherein R1 and R2 together represent alkylene with four, five or six carbon atoms optionally mono- or disubstituted by lower alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, lower alkoxy, amino, mono- or disubstituted amino, oxo, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms; oxaalkylene with one oxygen and three or four carbon atoms; or azaalkylene with one nitrogen and three or four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy-lower alkyl, carbamoyl-lower alkyl, N-mono- or N,N-disubstituted carbamoyl-lower alkyl, cycloalkyl, lower alkoxycarbonyl, carboxy, phenyl, substituted phenyl, pyridinyl, pyrimidinyl, or pyrazinyl; R4 represents hydrogen, lower alkyl, or halogen; and a N-oxide or a pharmaceutically acceptable salt of such a compound; and
(b) one or more protein phosphatase inhibitors selected from the group consisting of a Type I protein phosphatase inhibitor (PP1 inhibitor), a Type II protein phosphatase inhibitor (PP2 inhibitor) and a protein tyrosine phosphatase (PTP) inhibitor;
in combination with one or more pharmaceutically acceptable carriers.

### Claim 38 (depends on 36)

The combination of claim 36, wherein the PP1 inhibitor is Inhibitor-1 (I-1) or Inhibitor-2 (I-2).

### Claim 39 (depends on 36)

The combination of claim 36, wherein the PP2 inhibitor inhibits a Type II phosphatase selected from the group consisting of PP2A, PP2B, and PP2C.

### Claim 40 (depends on 36)

The combination of claim 36 wherein the protein phosphatase inhibitor inhibits PP1 and PP2A, and is selected from the group consisting of cantharidic acid and cantharidin.

### Claim 41 (depends on 36)

The combination of claim 36 wherein the PTP inhibitor is selected from the group consisting of L-P-bromotetramisole oxalate; 2(5H)-furanone, 4-hydroxy-5-(hydroxymethyl)-3-(1-oxohexadecyl)-,(5R)-(9Cl); and benzylphosphonic acid.

### Claim 42 (depends on 37)

The pharmaceutical composition of claim 37, wherein the PP1 inhibitor is Inhibitor-1 (I-1) or Inhibitor-2 (I-2).

### Claim 43 (depends on 37)

The pharmaceutical composition of claim 37, wherein the PP2 inhibitor inhibits a Type II phosphatase selected from the group consisting of PP2A, PP2B, and PP2C.

### Claim 44 (depends on 37)

The pharmaceutical composition of claim 37 wherein the protein phosphatase inhibitor inhibits PP1 and PP2A and is selected from the group consisting of cantharidic acid and cantharidin.

### Claim 45 (depends on 37)

The pharmaceutical composition of claim 37 wherein the PTP inhibitor is selected from the group consisting of L-P-bromotetramisole oxalate; 2(5H)-furanone, 4-hydroxy-5-(hydroxymethyl)-3-(1-oxohexadecyl)-,(5R)-(9Cl); and benzylphosphonic acid.

### Claim 46

A method of treating a proliferative disease in a subject, said method comprising administering to said subject a combination of:
(a) a Bcr-Abl, c-Kit and PDGF-R tyrosine kinase inhibitor of formula I
wherein R1 represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, or phenyl-lower alkyl; R2 represents hydrogen, lower alkyl, optionally substituted by one or more identical or different radicals R3, cycloalkyl, benzcycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted; and R3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amino, mono- or disubstituted amino, cycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted; or wherein R1 and R2 together represent alkylene with four, five or six carbon atoms optionally mono- or disubstituted by lower alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, lower alkoxy, amino, mono- or disubstituted amino, oxo, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms; oxaalkylene with one oxygen and three or four carbon atoms; or azaalkylene with one nitrogen and three or four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy-lower alkyl, carbamoyl-lower alkyl, N-mono- or N,N-disubstituted carbamoyl-lower alkyl, cycloalkyl, lower alkoxycarbonyl, carboxy, phenyl, substituted phenyl, pyridinyl, pyrimidinyl, or pyrazinyl; R4 represents hydrogen, lower alkyl, or halogen; and a N-oxide or a pharmaceutically acceptable salt of such a compound; and
(b) one or more protein phosphatase inhibitors selected from the group consisting of a Type I protein phosphatase inhibitor (PP1 inhibitor), a Type II protein phosphatase inhibitor (PP2 inhibitor) and a protein tyrosine phosphatase (PTP) inhibitor.

### Claim 47 (depends on 37)

A commercial package comprising the pharmaceutical composition of claim 37 wherein (a) and (b) are administered together, one after the other or separately in one combined unit dosage form or in two separate unit dosage forms.

### Claim 48 (depends on 36)

The combination of claim 36 wherein the proliferative disease is a tumor disease or cancer selected from the group consisting of breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, glioma, ovarian cancer, pancreatic cancer, neuroblastoma, head and neck cancer, bladder cancer, renal cancer brain cancer and gastric cancer.

### Claim 49 (depends on 37)

The pharmaceutical composition of claim 37 wherein the proliferative disease is a tumor disease or cancer selected from the group consisting of breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, glioma, ovarian cancer, pancreatic cancer, neuroblastoma, head and neck cancer, bladder cancer, renal cancer brain cancer and gastric cancer.

### Claim 50 (depends on 46)

The method of claim 46 wherein the wherein the proliferative disease is a tumor disease or cancer selected from the group consisting of breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, glioma, ovarian cancer, pancreatic cancer, neuroblastoma, head and neck cancer, bladder cancer, renal cancer, brain cancer and gastric cancer.

### Claim 51 (depends on 46)

The method of claim 46 wherein the PP1 inhibitor is Inhibitor-1 (I-1) or Inhibitor-2 (I-2).

### Claim 52 (depends on 46)

The method of claim 46 wherein the PP2 inhibitor inhibits a Type II phosphatase selected from the group consisting of PP2A, PP2B, and PP2C.

### Claim 53 (depends on 46)

The method of claim 46 wherein the protein phosphatase inhibitor inhibits PP1 and PP2A and is selected from the group consisting of cantharidic acid and cantharidin.

### Claim 54 (depends on 46)

The method of claim 46 wherein the PTP inhibitor is selected from the group consisting of L-P-bromotetramisole oxalate; 2(5H)-furanone, 4-hydroxy-5-(hydroxymethyl)-3-(1-oxohexadecyl)-,(5R)-(9Cl); and benzylphosphonic acid.

### Claim 55 (depends on 36)

The combination of claim 36, wherein (a) is 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino-N-[5-(4-methyl-1H-imidazol-1-yl)-3-trifluoromethyl)phenyl]benzamide.
